Twist Bioscience Corp (TWST)
47.50  +0.11 (0.23%)

Twist Bioscience Corp is a biotechnology company that focuses on revolutionizing the way synthetic DNA is produced. Utilizing its proprietary synthesis platform, the company specializes in creating high-quality, cost-effective DNA for a variety of applications, including healthcare, agriculture, and industrial biotechnology. The core technology is designed to meet the growing demand for synthetic genetic material, enabling advancements in fields such as gene therapy, personalized medicine, and synthetic biology. By providing tailored DNA solutions, Twist Bioscience aims to accelerate innovation and breakthroughs in life sciences and other industries reliant on genetic engineering.

SummaryNewsPress ReleasesChartHistorical
Previous Close47.39
Open47.93
Bid46.50
Ask51.25
Day's Range46.56 - 48.09
52 Week Range27.41 - 60.90
Volume814,078
Market Cap2.42B
PE Ratio (TTM)-13.19
EPS (TTM)-3.6
Dividend & YieldN/A (N/A)
1 Month Average Volume939,654

News & Press Releases

Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investmentsbenzinga.com
Cathie Wood, founder and CEO of ARK Investment Management LLC, defended the future of artificial intelligence investments while highlighting Tesla Inc. as a cornerstone of technological innovation during a recent podcast appearance with SoFi's Head of Investment Strategy, Liz Thomas.
Via Benzinga · November 29, 2024
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?benzinga.com
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
Via Benzinga · November 26, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 18, 2024
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In Novembermarkets/com
Via Benzinga · November 18, 2024
Top Wall Street Forecasters Revamp Twist Bioscience Price Expectations Ahead Of Q4 Earningsbenzinga.com
Via Benzinga · November 18, 2024
Twist Bioscience Earnings Previewbenzinga.com
Via Benzinga · November 15, 2024
Deep Dive Into Twist Bioscience Stock: Analyst Perspectives (5 Ratings)benzinga.com
Via Benzinga · October 1, 2024
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumpsbenzinga.com
Twist Bioscience's Q4 results topped estimates, with revenue up 27% YoY. Fiscal 2025 guidance includes revenue growth and a targeted gross margin of 48%.
Via Benzinga · November 18, 2024
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · November 18, 2024
Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results
Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the fourth quarter and full year fiscal 2024 ended September 30, 2024.
By Twist Bioscience Corporation · Via Business Wire · November 18, 2024
Earnings Scheduled For November 18, 2024benzinga.com
Via Benzinga · November 18, 2024
Twist Bioscience to Present at 7th Annual Evercore HealthCONx Conference
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 10:00 a.m. Eastern Time in Coral Gables, Florida.
By Twist Bioscience Corporation · Via Business Wire · November 14, 2024
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 147,800 equity awards, consisting of 110,300 restricted stock units (“RSUs”) to 43 recently hired individuals and an individually negotiated award of up to 37,500 performance stock units (“PSUs”) to Colby Souders, a recently hired VP, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards were granted under Twist’s Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
By Twist Bioscience Corporation · Via Business Wire · November 7, 2024
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500benzinga.com
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.
Via Benzinga · October 31, 2024
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody
By Absci Corporation · Via GlobeNewswire · October 31, 2024
Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the FlexPrep™ Ultra-High Throughput Library Preparation Kit, designed with a proprietary Twist-developed enzyme to enable throughput at a low cost, and accelerate the adoption of NGS by microarray users in population and agricultural genomics (agrigenomics).
By Twist Bioscience Corporation · Via Business Wire · October 30, 2024
Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, before the opening of the market on November 18, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com.
By Twist Bioscience Corporation · Via Business Wire · October 24, 2024
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator.
By Twist Bioscience Corporation · Via Business Wire · October 22, 2024
Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses.
By Twist Bioscience Corporation · Via Business Wire · October 15, 2024
Coeur Mining, Medical Properties Trust And RH Are Among Top 7 Mid Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?benzinga.com
7 mid-cap stocks with impressive gains last week: CDE, MPW, NGD, RH, AUR, TWST, ALHC. Positive news and financial results drove the surge.
Via Benzinga · September 15, 2024
Twist Bioscience Achieves LEED Certification for Sustainable Operations and Maintenance
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the U.S. Green Building Council (USGBC) awarded the company’s Wilsonville, OR facility LEED certification, meeting sustainability standards for its building, operations and maintenance.
By Twist Bioscience Corporation · Via Business Wire · September 12, 2024
Twist Bioscience Releases 2024 Corporate Responsibility Report and Quantifies Carbon Footprint of Oligo Manufacturing Process for NGS Target Enrichment Panels
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today released its 2024 corporate responsibility report detailing Twist’s approach to sustainability, social responsibility and ethics. The report highlights Twist’s ongoing commitment to advancing sustainable initiatives to best serve customers, communities and the planet.
By Twist Bioscience Corporation · Via Business Wire · September 9, 2024
Twist Bioscience to Present at Baird Global Healthcare Conference 2024
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird Global Healthcare Conference 2024 in New York City on Tuesday, September 10 at 2:35 p.m. Eastern Time.
By Twist Bioscience Corporation · Via Business Wire · August 27, 2024
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END
Via FinancialNewsMedia · August 14, 2024
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
PALM BEACH, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The technological shift driven by the rise of artificial intelligence (AI) is giving patients in the USA cautious optimism towards the potential of generative AI in healthcare. In order to safely bring AI into the healthcare space, state governments across the USA are working on how to regulate its implementation. The potential to enhance accuracy and speed in diagnostics, analyzing eye scans and predicting complications, and even designing new drugs, the potential for AI in healthcare is too big to ignore. Reaching the goal of safely bringing AI into the medical space still requires lots of research and development, with several tech innovators recently updating the market with their latest developments, including: Avant Technologies Inc. (OTCQB: AVAI), Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), Exscientia plc (NASDAQ: EXAI), Twist Bioscience Corporation (NASDAQ: TWST) and IQVIA Holdings Inc. (NYSE: IQV).
By FN Media Group LLC · Via GlobeNewswire · August 14, 2024